Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
06 août 2024 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
29 mai 2024 07h00 HE
|
Kynexis
NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain...
The BC Schizophrenia Society Calls on British Columbians to #StandAgainstStigma this National Schizophrenia and Psychosis Awareness Day
24 mai 2024 10h00 HE
|
BC Schizophrenia Society
VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- The British Columbia Schizophrenia Society (BCSS), a provincial non-profit organization dedicated to supporting individuals and families...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
01 mai 2024 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16 avr. 2024 02h30 HE
|
Nxera Pharma
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion of...
Anorexia Nervosa Treatment Advances with New 2024 Pipeline Landscape Report
27 févr. 2024 11h06 HE
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Anorexia Nervosa - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A Comprehensive Overview of Emerging...
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
04 janv. 2024 06h30 HE
|
Kynexis
KYN-5356 is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathwayTopline results are expected in the second half of 2024 NAARDEN, The Netherlands,...
Understanding Resilience to Schizophrenia through Genetics - A Free Webinar from the Brain & Behavior Research Foundation
05 déc. 2023 10h45 HE
|
Brain & Behavior Research Foundation
New York, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Understanding Resilience to Schizophrenia through Genetics” on Tuesday,...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
07 nov. 2023 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
07 nov. 2023 05h00 HE
|
Kynexis
- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia - €57 Million Series A Led by Forbion ...